Ftse Mib
35.928,17
-1,49%
DAX
21.296,03
-1,91%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
95.299,84
-2,46%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Inventiva (IVA) Inventiva (IVA) Notizie

IVA

Inventiva (IVA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:IVA
DataOraFonteTitoloSimboloCompagnia
29/01/202522:00GlobeNewswire Inc.Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of HepatologyEU:IVAInventiva
24/01/202522:00GlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
22/01/202522:00GlobeNewswire Inc.Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025EU:IVAInventiva
17/12/202422:00GlobeNewswire Inc.Inventiva to present at the 43rd Annual J.P. Morgan Healthcare ConferenceEU:IVAInventiva
16/12/202408:30GlobeNewswire Inc.Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 millionEU:IVAInventiva
12/12/202422:00GlobeNewswire Inc.Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024EU:IVAInventiva
21/11/202422:00GlobeNewswire Inc.Inventiva reports 2024 Third Quarter Financial Information¹EU:IVAInventiva
20/11/202422:00GlobeNewswire Inc.Combined General Meeting of December 11, 2024 - Availability of the preparatory documentsEU:IVAInventiva
15/11/202422:00GlobeNewswire Inc.Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker sessionEU:IVAInventiva
30/10/202421:00GlobeNewswire Inc.Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASHEU:IVAInventiva
21/10/202414:30GlobeNewswire Inc.Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024EU:IVAInventiva
14/10/202419:45GlobeNewswire Inc.Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrantsEU:IVAInventiva
14/10/202408:35GlobeNewswire Inc.Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportEU:IVAInventiva
14/10/202408:30GlobeNewswire Inc.Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH studyEU:IVAInventiva
25/09/202422:00GlobeNewswire Inc.Inventiva provides a corporate update and reports its unaudited 2024 first-half financial resultsEU:IVAInventiva
31/07/202422:00GlobeNewswire Inc.Inventiva Reports Preliminary 2024 First-Half Financial Information¹EU:IVAInventiva
25/07/202422:00GlobeNewswire Inc.Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorEU:IVAInventiva
18/07/202408:30GlobeNewswire Inc.Inventiva announces a €20.1 million issuance of royalty certificatesEU:IVAInventiva
05/07/202422:00GlobeNewswire Inc.Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position  EU:IVAInventiva
05/07/202422:00GlobeNewswire Inc.Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièrEU:IVAInventiva
21/06/202422:05GlobeNewswire Inc.Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024  EU:IVAInventiva
21/06/202422:05GlobeNewswire Inc.DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024EU:IVAInventiva
21/06/202422:00GlobeNewswire Inc.Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024  EU:IVAInventiva
21/06/202422:00GlobeNewswire Inc.Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024EU:IVAInventiva
30/05/202408:30GlobeNewswire Inc.Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoiresEU:IVAInventiva
30/05/202408:30GlobeNewswire Inc.Combined General Meeting of June 20, 2024 - Availability of the preparatory documentsEU:IVAInventiva
30/05/202408:30GlobeNewswire Inc.Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024EU:IVAInventiva
30/05/202408:30GlobeNewswire Inc.Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024EU:IVAInventiva
22/05/202422:00GlobeNewswire Inc.Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024EU:IVAInventiva
21/05/202422:00GlobeNewswire Inc.Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activitésEU:IVAInventiva
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:IVA

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
G
Generali
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
SPM
Saipem
BIT
NEXI
Nexi S.p.A
BIT
PIRC
Pirelli & C
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci